Shanghai Sinotau Biotech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer.
Shanghai Boyue Biotechnology Co. Ltd. has disclosed hepatocyte growth factor receptor (HGFR; MET) and tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc., and Kelonia Therapeutics Inc. have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics.
Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.
Pompe disease is caused by a deficiency in the lysosomal enzyme acid α-glucosidase (GAA) that leads to accumulation of glycogen in the lysosomes, mainly seen in skeletal and cardiac muscles. Researchers from Duke University have developed a new murine model of Pompe disease, which recapitulates human infantile-onset disease. This model harbors the c.1826dupA mutation in the murine Gaa gene, which resembles the human GAA c.1826dupA (p.Y609*) mutation seen in infantile-onset Pompe disease.
Investigators from Tanta University and affiliated organizations have reported the discovery and preclinical characterization of novel carbonic anhydrase (CA) isoform II inhibitors as potential antiglaucoma agents.
RSS
